Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Ascendis Pharma ( (ASND) ) is now available.
On July 28, 2025, Ascendis Pharma announced that the U.S. FDA approved SKYTROFA for the treatment of adult growth hormone deficiency, expanding its use beyond pediatric cases. This approval, based on a successful Phase 3 trial, marks a significant milestone for the company and could enhance its market position in the endocrine disorder treatment sector. Additionally, Ascendis plans to initiate trials for several other conditions in the fourth quarter of 2025, indicating a robust pipeline and potential future growth.
The most recent analyst rating on (ASND) stock is a Buy with a $165.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
Ascendis Pharma’s stock reflects a mix of strong revenue growth and innovative product development, offset by significant operational losses and financial instability. The technical analysis shows strong momentum, but valuation remains challenging with negative earnings. The earnings call further underscores the duality of growth potential and financial constraints.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, focusing on developing innovative therapies for rare endocrine disorders. Their primary products include TransCon technologies, which are designed to improve the efficacy and safety of existing drug compounds.
Average Trading Volume: 457,418
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.11B
Learn more about ASND stock on TipRanks’ Stock Analysis page.